The occurrence of a severe infection during the first month of care is a strong predictor of one-year mortality among…
Articles by Patricia Inacio, PhD
Standard therapies used to ANCA-associated vasculitis (AAV), like cyclophosphamide or Rituxan (rituximab), appear to be of benefit in patients who…
The frequency of ANCA-associated vasculitis (AAV) appears to increase with exposure to carbon monoxide and colder climates, with patients more often…
The presence of atypical ANCA antibodies in people with underlying eye inflammatory disease is not linked to severe vessel inflammation…
A case report of a patient with eosinophilic granulomatosis with polyangiitis (EGPA), with the disease affecting both the heart and…
Children with eosinophilic granulomatosis with polyangiitis (EGPA) have specific disease symptoms that differ from those seen in adults with the…
Patients with granulomatosis with polyangiitis whose autoantibodies are against the myeloperoxidase protein (MPO) have increased disease activity at diagnosis but…
Patients with ANCA-associated vasculitis using an immunosuppressive therapy may be at risk of late-onset pneumonia caused by opportunistic Pneumocystis jirovecii infection, a…
Men with ANCA-associated vasculitis (AAV) presenting kidney inflammation are more likely than women to progress into end-stage renal disease,…
In patients with ANCA-associated vasculitis (AAV), the reappearance of ANCA autoantibodies may work as a biomarker for predicting relapse,…